Robert Kuttner

Robert Kuttner is co-founder and co-editor of The American Prospect, as well as a distinguished senior fellow of the think tank Demos. He was a longtime columnist for Business Week and continues to write columns in The Boston Globe. He is the author of Obama's Challenge and other books.

Recent Articles

Ironically, Gore's Biggest Worry May be About Oil

The record economic boom is near a tipping point. Although no serious
inflation is being generated by the sizzling economy, increases in oil prices show up in the general price index. They also worsen America's balance of trade.

Meanwhile, the weakness of the euro is depressing profits that American
companies earn abroad. On all these counts, the stock market is getting very nervous.

A big stock market correction would cool off both consumer and business spending. It might scare off the foreign investors who keep buying our bonds. In this context, a misstep by the inflation-phobic Federal Reserve could help send the economy into deep recession.

Let's Have Real Shared Sacrifice

Retailers are not expecting a great Christmas season this year. Shoppers have less money
in their pockets and more worries about their economic future. The very act of
shop-til-you-drop, always a little bizarre as a form of Yuletide expression, feels especially
unseemly in wartime, even when rationalized as a patriotic act of economic stimulus.

Prescription for Failure

Prescription drug benefits are shaping up as one of the defining issues in this fall's campaign. Drugs are now the fastest-growing component of medical care. Elderly people spend more on drugs than on doctor bills. HMOs are squeezing other kinds of care because of their own rising drug costs.


There are really two big questions here: Should more Americans get more drug coverage, and should government play a direct role in limiting drug prices?


The reasonable answer to both questions is a resounding yes.


News Pollution

Readers of the Sunday New York Times Magazine were treated on April 1
to an extensive advertising supplement on allergies and asthma. The supplement
ran from page 30 to page 42, with regular Times Magazine page
numbering. The ostensible news copy was prepared by an outside agency; the
section carried the disclaimer, in small type, that it was not based on reporting
or editing by the Times.

Pages